Literature DB >> 15307183

Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length.

Kate J Green1, John J Miles, Judy Tellam, Wendy J M van Zuylen, Geoff Connolly, Scott R Burrows.   

Abstract

The BZLF1 antigen of Epstein-Barr virus includes three overlapping sequences of different lengths that conform to the binding motif of human leukocyte antigen (HLA) B*3501. These 9-mer (56LPQGQLTAY64), 11-mer (54EPLPQGQLTAY64), and 13-mer (52LPEPLPQGQLTAY64) peptides all bound well to B*3501; however, the CTL response in individuals expressing this HLA allele was directed strongly and exclusively towards the 11-mer peptide. In contrast, EBV-exposed donors expressing HLA B*3503 showed no significant CTL response to these peptides because the single amino acid difference between B*3501 and B*3503 within the F pocket inhibited HLA binding by these peptides. The extraordinarily long 13-mer peptide was the target for the CTL response in individuals expressing B*3508, which differs from B*3501 at a single position within the D pocket (B*3501, 156Leucine; B*3508, 156Arginine). This minor difference was shown to enhance binding of the 13-mer peptide, presumably through a stabilizing interaction between the negatively charged glutamate at position 3 of the peptide and the positively charged arginine at HLA position 156. The 13-mer epitope defined in this study represents the longest class I-binding viral epitope identified to date as a minimal determinant. Furthermore, the potency of the response indicates that peptides of this length do not present a major structural barrier to CTL recognition. Copyright 2004 Wiley-VCH Verlag GmbH & Co.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307183     DOI: 10.1002/eji.200425193

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family.

Authors:  Christina Bade-Döding; Alex Theodossis; Stephanie Gras; Lars Kjer-Nielsen; Britta Eiz-Vesper; Axel Seltsam; Trevor Huyton; Jamie Rossjohn; James McCluskey; Rainer Blasczyk
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

2.  T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Authors:  Melissa J Rist; Michelle A Neller; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

3.  Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.

Authors:  Damien J Zanker; Sara Oveissi; David C Tscharke; Mubing Duan; Siyuan Wan; Xiaomu Zhang; Kun Xiao; Nicole A Mifsud; James Gibbs; Lenny Izzard; Daniel Dlugolenski; Pierre Faou; Karen L Laurie; Nathalie Vigneron; Ian G Barr; John Stambas; Benoît J Van den Eynde; Jack R Bennink; Jonathan W Yewdell; Weisan Chen
Journal:  J Immunol       Date:  2019-05-15       Impact factor: 5.422

4.  Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.

Authors:  Uma Malhotra; Fusheng Li; Jessica Nolin; Megan Allison; Hong Zhao; James I Mullins; Steve Self; M Juliana McElrath
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  A single amino acid difference within the alpha-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL.

Authors:  Robert H Mealey; Jae-Hyung Lee; Steven R Leib; Matt H Littke; Travis C McGuire
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

6.  Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503.

Authors:  Vilasack Thammavongsa; Malinda Schaefer; Tracey Filzen; Kathleen L Collins; Mary Carrington; Naveen Bangia; Malini Raghavan
Journal:  Immunogenetics       Date:  2009-12       Impact factor: 2.846

7.  An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.

Authors:  Melissa J Bell; Rachel J M Abbott; Nathan P Croft; Andrew D Hislop; Scott R Burrows
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

Review 8.  Coping with loss of perfection in the MHC class I peptide repertoire.

Authors:  Nicolas Blanchard; Nilabh Shastri
Journal:  Curr Opin Immunol       Date:  2008-02       Impact factor: 7.486

9.  Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.

Authors:  Mathew Clement; Kristin Ladell; Julia Ekeruche-Makinde; John J Miles; Emily S J Edwards; Garry Dolton; Tamsin Williams; Andrea J A Schauenburg; David K Cole; Sarah N Lauder; Awen M Gallimore; Andrew J Godkin; Scott R Burrows; David A Price; Andrew K Sewell; Linda Wooldridge
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

10.  HIV control through a single nucleotide on the HLA-B locus.

Authors:  Henrik N Kløverpris; Mikkel Harndahl; Alasdair J Leslie; Jonathan M Carlson; Nasreen Ismail; Mary van der Stok; Kuan-Hsiang Gary Huang; Fabian Chen; Lynn Riddell; Dewald Steyn; Dominique Goedhals; Cloete van Vuuren; John Frater; Bruce D Walker; Mary Carrington; Thumbi Ndung'u; Søren Buus; Philip Goulder
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.